VBI Vaccines (VBIV) has released an update.
VBI Vaccines Inc. has recently made strategic financial moves, including the amendment of its loan agreement to ease certain financial covenants and a series of purchase agreements involving the sale of intellectual property and manufacturing facility assets. These agreements, primarily with Brii Biosciences, involve adjusting the terms of their collaboration, including making certain licenses perpetual and royalty-free. These transactions are part of VBI’s broader strategy to manage its financial obligations and advance its vaccine development programs, potentially strengthening its position within the biopharmaceutical sector.
For further insights into VBIV stock, check out TipRanks’ Stock Analysis page.
